Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
Eur J Med Chem. 2017 Nov 10;140:349-382. doi: 10.1016/j.ejmech.2017.09.034. Epub 2017 Sep 22.
Since the antitumor activity of cisplatin was discovered in 1967 by Rosenberg, platinum-based anticancer drugs have played an important role in chemotherapy in clinic. Nevertheless, platinum anticancer drugs also have caused severe side effects and cross drug resistance which limited their applications. Therefore, a significant amount of efforts have been devoted to developing new platinum-based anticancer agents with equal or higher antitumor activity but lower toxicity. Until now, a large number of platinum-based complexes have been prepared and extensively investigated in vitro and in vivo. Among them, some platinum-based complexes revealing excellent anticancer activity showed the potential to be developed as novel type of anticancer agents. In this account, we present such platinum-based anticancer complexes which owning various types of ligands, such as, amine carrier ligands, leaving groups, reactive molecule, steric hindrance groups, non-covalently binding platinum (II) complexes, Platinum(IV) complexes and polynuclear platinum complexes. Overall, platinum-based anticancer complexes reported recently years upon modern structure are emphasized.
自罗森伯格（Rosenberg）于 1967 年发现顺铂的抗肿瘤活性以来，基于铂的抗癌药物在临床上的化疗中发挥了重要作用。然而，铂类抗癌药物也会引起严重的副作用和交叉耐药性，从而限制了它们的应用。因此，人们投入了大量的精力来开发具有同等或更高抗肿瘤活性但毒性更低的新型铂类抗癌药物。到目前为止，已经制备了大量的铂类配合物，并在体外和体内进行了广泛的研究。其中，一些具有优异抗肿瘤活性的铂类配合物显示出作为新型抗癌药物开发的潜力。在本报告中，我们介绍了具有各种类型配体的基于铂的抗癌配合物，如胺载体配体、离去基团、反应性分子、空间位阻基团、非共价结合的铂(II)配合物、铂(IV)配合物和多核铂配合物。总的来说，强调了近年来基于现代结构报道的基于铂的抗癌配合物。
